What happened
On 15 December 2025, Sanofi announced that its Phase 3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (MS) did not meet its main goal: tolebrutinib was not shown to delay the time to disability progression confirmed over six months, compared with placebo. That measure combines worsening on the EDSS disability scale, a timed 25-foot walk and a hand-dexterity test. The registry lists 767 participants; according to Sanofi, people aged 18 to 55 were assigned two to one to daily tolebrutinib tablets or placebo for up to about five years. Sanofi said that the preliminary safety profile was consistent with earlier tolebrutinib studies and that drug-induced liver injury is an identified risk of the drug. Based on these results, Sanofi said it will not seek regulatory approval of tolebrutinib for primary progressive MS. The announcement gives no figures. On 11 November 2026, ClinicalTrials.gov listed the study as completed on 14 November 2025, with no results posted.
What this means for people with MS
For people with primary progressive MS, this Phase 3 study did not show that tolebrutinib slows disability progression, and Sanofi does not plan to seek approval for that form of MS. The result does not change the separate EU authorisation of Cenrifki (tolebrutinib) for adults with secondary progressive MS without relapses in the previous two years, which rests on a different study, HERCULES. Because only a short company statement is available, the size of any difference, the secondary results and the full safety data cannot be assessed. The study had centres in many countries, including Greece; it has ended and is not accepting participants.
About the approach studied in this programme: Tolebrutinib / Cenrifki
Tolebrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a signalling protein in immune cells. The approach aims to reduce inflammatory activity in MS, including processes linked to disability progression; it has not been shown to restore myelin.
Approach source: EMA — Cenrifki medicine overview ↗
- What kind of evidence exists?
- Official Sanofi announcement; study design and completion from ClinicalTrials.gov and the EU clinical trials register
- How reliable is this source?
- Official Sanofi announcement for the main result, the safety statement and the decision not to seek approval; ClinicalTrials.gov and the EU Clinical Trials Information System for study design, size, countries and completion. The announcement contains no numerical results; no registry results and no peer-reviewed PERSEUS report were found on 11 November 2026.
- Research event/source date
- Published by MyelinWatch
- Last substantive MyelinWatch update